PRESS RELEASE published on 10/18/2024 at 15:49, 1 year 6 months ago EQS-Adhoc: EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor EMA grants PRIME status to Pentixapharm’s lead candidate Ga68-PentixaFor, offering early and proactive support for radiodiagnostic development in primary aldosteronism. PentixaFor aims to transform diagnostic subtyping with non-invasive PET imaging targeting CXCR4 Pentixapharm Ga68-PentixaFor Primary Aldosteronism PRIME Status Radiodiagnostic
BRIEF published on 10/03/2024 at 12:03, 1 year 7 months ago Pentixapharm Holding AG Lists on Frankfurt Stock Exchange Frankfurt Stock Exchange IPO Biopharmaceuticals Radiopharmaceuticals Pentixapharm
BRIEF published on 10/03/2024 at 12:03, 1 year 7 months ago Pentixapharm Holding AG est cotée à la Bourse de Francfort Bourse De Francfort Introduction En Bourse Produits Biopharmaceutiques Produits Radiopharmaceutiques Pentixapharm
PRESS RELEASE published on 10/03/2024 at 11:58, 1 year 7 months ago Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange Pentixapharm Holding AG debuts in Prime Standard of Frankfurt Stock Exchange with IPO. Focus on radiopharmaceuticals for blood cancers Frankfurt Stock Exchange IPO Biopharmaceutical Radiopharmaceuticals Pentixapharm
BRIEF published on 10/01/2024 at 18:53, 1 year 7 months ago Pentixapharm Holding AG Sets IPO Placement Price at EUR 5.10 per Share Securities Frankfurt Stock Exchange IPO Market Capitalization Pentixapharm
BRIEF published on 10/01/2024 at 18:53, 1 year 7 months ago Pentixapharm Holding AG fixe le prix de son introduction en bourse à 5,10 euros par action Titres Bourse De Francfort Capitalisation Boursière Introduction En Bourse Pentixapharm
PRESS RELEASE published on 10/01/2024 at 18:48, 1 year 7 months ago EQS-Adhoc: Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed Pentixapharm Holding AG sets IPO placement price at EUR 5.10 per share, placing all 3.9 million offer shares. Gross proceeds reach EUR 19.9 million. Post-money market capitalization at EUR 126.5 million IPO Market Capitalization Pentixapharm Holding AG Placement Price Offer Shares
PRESS RELEASE published on 09/24/2024 at 11:51, 1 year 7 months ago Original-Research: Pentixapharm Holding AG (von BankM AG): n.a. Pentixapharm Holding AG von BankM AG eingestuft. Präziser Theranostic-Ansatz mit validiertem Target. Potenzial in Präzisionsonkologie. Risikoadjustierte Bewertung des Eigenkapitals. Vollständige Analyse unter: http://www.more-ir.de/d/30855.pdf BankM AG Pentixapharm Holding AG Theranostic-Ansatz Präzisionsonkologie Bewertung Eigenkapital
BRIEF published on 09/23/2024 at 12:20, 1 year 7 months ago Pentixapharm Holding AG Sets Price Range for Planned IPO Frankfurt Stock Exchange Clinical Trials IPO Radiopharmaceuticals Pentixapharm
BRIEF published on 09/23/2024 at 12:20, 1 year 7 months ago Pentixapharm Holding AG fixe la fourchette de prix de son introduction en bourse Bourse De Francfort Essais Cliniques Introduction En Bourse Produits Radiopharmaceutiques Pentixapharm
Published on 05/09/2026 at 01:30, 1 day 18 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 19 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 16:05, 3 hours 27 minutes ago RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 5 hours 32 minutes ago MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 7 hours 47 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 22 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/07/2026 at 19:15, 3 days ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL